Indegene Limited reported an 8.0% year-over-year revenue growth for Q2 FY25, reaching INR 6,868 million, with a profit after tax of INR 917 million, up 22.3% from the previous year.

The company maintains strong client relationships, with 68 active clients contributing to its revenue primarily from biopharma.

The PAT margin improved to 13.4%, supported by zero-debt servicing costs and enhanced productivity.

The company emphasizes its digital-first approach and healthcare expertise in a rapidly growing market.